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Heterogeneous Nuclear Ribonucleoprotein K Supports Vesicular
Stomatitis Virus Replication by Regulating Cell Survival and Cellular
Gene Expression
Phat X. Dinh,a,b Anshuman Das,a,b Rodrigo Franco,a Asit K. Pattnaika,b
School of Veterinary Medicine and Biomedical Sciencesa and Nebraska Center for Virology,b University of Nebraska—Lincoln, Lincoln, Nebraska, USA
The heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a member of the family of hnRNPs and was recently shown in a
genome-wide small interfering RNA (siRNA) screen to support vesicular stomatitis virus (VSV) growth. To decipher the role of
hnRNP K in VSV infection, we conducted studies which suggest that the protein is required for VSV spreading. Virus binding to
cells, entry, and nucleocapsid uncoating steps were not adversely affected in the absence of hnRNP K, whereas viral genome tran-
scription and replication were reduced slightly. These results indicate that hnRNP K is likely involved in virus assembly and/or
release from infected cells. Further studies showed that hnRNP K suppresses apoptosis of virus-infected cells, resulting in in-
creased cell survival during VSV infection. The increased survival of the infected cells was found to be due to the suppression of
proapoptotic proteins such as Bcl-XS and Bik in a cell-type-dependent manner. Additionally, depletion of hnRNP K resulted in
not only significantly increased levels of T-cell-restricted intracellular antigen 1 (TIA1) but also switching of the expression of
the two isoforms of the protein (TIA1a and TIA1b), both of which inhibited VSV replication. hnRNP Kwas also found to sup-
port expression of several cellular proteins known to be required for VSV infection. Overall, our studies demonstrate hnRNP K
to be a multifunctional protein that supports VSV infection via its role(s) in suppressing apoptosis of infected cells, inhibiting
the expression of antiviral proteins, andmaintaining the expression of proteins required for the virus.
The K homology (KH) domain-containing subfamily of heter-ogeneous nuclear ribonucleoproteins (hnRNPs) has five
members, namely, the hnRNP K (the prototypic member of the
subfamily), the poly(C) binding protein 1 (PCBP1, also known as
hnRNP E1), PCBP2 (hnRNP E2), PCBP3, and PCBP4. All mem-
bers of this subfamily carry three KH domains, which are respon-
sible for binding to C- or U-rich regions in RNA and/or DNA (1).
These proteins, and in particular, hnRNP K, are known to partic-
ipate in various cellular processes such as chromatin organization,
mRNA translation, regulation of transcription and splicing, RNA
shuttling, mRNA and/or protein stability, and cell survival (2, 3).
hnRNP K interacts with numerous cellular partners, including
oncogenic proteins such as tyrosine kinases (Lck and c-Src) (4)
and serine/threonine kinases (extracellular signal-regulated ki-
nase/mitogen-activated protein kinase [ERK/MAPK]) (5), and
plays critical roles in cell growth, tissue development and differ-
entiation including red blood cell differentiation (6), ovary devel-
opment (7), and neuronal development (8). The observation that
hnRNP K is highly expressed in multiple cancerous tissues (9–12)
suggests its possible roles in cancer development and tumorigen-
esis. On the other hand, its sequestration, deficiency, or degrada-
tion marks the initial step for apoptotic progression (13–15).
hnRNPKhas also been demonstrated to play key roles inmany
viral infections. While interacting with the 5= untranslated region
(UTR), it supports replication of enterovirus 71 (16, 17); its inter-
action with the hepatitis B virus (HBV) genome leads to increased
viral DNA synthesis (18, 19). Dengue virus and herpes simplex
virus 1 (HSV-1) also have been shown to require the functions of
hnRNPK in progeny virus production (20, 21). hnRNPKnot only
serves as a splicing factor for Tat/Rev exon 3 ofHIV-1 (22) but also
interacts with viral components of Sindbis virus, chikungunya
virus, hepatitis C virus, African swine fever virus, human cyto-
megalovirus (CMV), and Epstein-Barr virus (23–28) to support
virus growth.
Vesicular stomatitis virus (VSV) is an enveloped, nonseg-
mented, negative-stranded RNA virus in theRhabdoviridae family
and replicates exclusively in the cytoplasm of infected cells. Re-
cently, we demonstrated that PCBP2 and PCBP1 (PCBP1/2), two
members of the KH-domain-containing subfamily of hnRNPs,
inhibit VSV growth by negatively regulating viral gene expression
(29). Although the mechanism by which the PCBPs inhibit viral
gene expression and virus growth is unknown at this time, further
studies have revealed that the infected cells induce formation of
stress granule (SG)-like structures that contain not only PCBP2
but also other cellular RNA-binding proteins such as the T-cell-
restricted intracellular antigen 1 (TIA1) and TIA1-related (TIAR)
proteins, which have been shown to inhibit VSV replication (30).
hnRNP K resides predominantly in the nucleus (31); however,
studies have shown that in VSV-infected cells, it is translocated
into the cytoplasm (32). The reason(s) for this altered subcellular
localization in infected cells is unclear, but it is possible that hn-
RNP Kmight be directly or indirectly involved in VSV replication
and growth. This contention is further strengthened by the iden-
tification of hnRNP K as one of the host factors required for VSV
infection in a genome-wide small interfering RNA (siRNA) screen
(33). Since both PCBP2 and hnRNP K proteins are in the same
subfamily with similar domain organizations and functions, it is
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surprising to observe opposite effects of these two proteins on
VSV infection. In this communication, we conducted studies to
examine the role of hnRNP K in supporting VSV infection. Our
studies show that hnRNP K supports virus growth and infection
by enhancing the cell viability of infected cells. Further studies
reveal that the enhanced cell viability is due to increased levels of
several antiapoptotic factors such as Bcl-XL, Bcl-2, and Bag1
and/or decreased levels of proapoptotic factors such as Bcl-XS and
Bik in a cell-type-dependent manner. In addition, our studies re-
veal that hnRNP K modulates expression of certain cellular pro-
teins that have been found to be required for VSV replication,
while also downregulating expression of certain cellular proteins
previously shown to inhibit virus replication. The key findings
reported here suggest that hnRNP K supports VSV growth by
prolonging survival of the virus-infected cells andmodulating ex-
pression of cellular factors influencing virus growth.
MATERIALS AND METHODS
Cell culture and reagents. Monolayer cultures of HeLa (ATCC CCL2),
HEK293, Huh7, and MCF-7 cells were maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 8% fetal bovine serum
(FBS) and the antibiotics penicillin (100 units/ml), kanamycin (20 units/
ml), and streptomycin (20 units/ml) (PKS). Baby hamster kidney (BHK-
21) cells were maintained in minimal essential medium (MEM) supple-
mented with 5% fetal bovine serum (FBS) and the antibiotics (PKS).
Immortalized murine embryonic fibroblasts (MEFs) from wild-type (wt)
and TIA1-knockout mice (34) were obtained from P. Anderson (Harvard
University) and were maintained as described previously (30).
Viruses and VSV RNP or nucleocapsid (NC) preparation. Stocks of
wt VSV, VSV expressing enhanced green fluorescent protein (eGFP) and
eGFP fused to the VSV phosphoprotein (VSV-eGFP and VSV-PeGFP,
respectively) were prepared as described earlier (35, 36). VSVG (VSV
lacking the G protein) virus encoding PeGFP and VSV ribonucleocapsids
(RNPs) were prepared as previously described (29). VSV-PLuc was con-
structed by replacing the eGFP coding sequence in the VSV-PeGFP back-
bone (35) with the coding sequence of the luciferase (Luc) protein of
Renilla reniformis. First, the coding sequence of Renilla luciferase was
amplified from plasmid pRL-TK (Promega) by primers containing an
NotI site. After digestion with NotI, the fragment was inserted into a
VSV-PeGFP plasmid (35), which was digested with NotI to remove the
eGFP sequences. This resulted in the insertion of the entire coding se-
quences of luciferase in frame following amino acid 196 of the P protein.
Subsequently, VSV-PLucwas recovered according to a protocol described
previously (36).
Virus titration and infection.Virus titers were determined by plaque
assay on BHK-21 and HeLa cells. Virus infection in each experiment was
performed at a multiplicity of infection (MOI) of 1 or 0.01 PFU per cell,
except where indicated otherwise.
Antibodies.Anti-M (23H12)monoclonal antibodieswere kindly pro-
vided by D. Lyles. Antibodies for actin (mouse monoclonal; sc-47778),
PCBP1 (goat polyclonal; sc-16504), PCBP2 (mouse monoclonal; sc-
101136), hnRNP K (mouse monoclonal; sc-28380), TIA1 (goat poly-
clonal; sc-1751), GS28 (rabbit polyclonal; sc-15270), NF90 (rabbit poly-
clonal; sc-22530), procaspase 3 (mouse monoclonal; sc-166589), alanine
deaminase-like (ADAL) (rabbit polyclonal; sc-138086), FLICE-inhibitory
protein (FLIP) (mouse monoclonal; sc-5276), Bad (mouse monoclonal;
sc-8044), Bak (rabbit polyclonal; sc-832), and Noxa (rabbit polyclonal;
sc-30209) were purchased from Santa Cruz Biotechnology, Inc. Anti-
hemagglutinin (HA)monoclonal antibody HA-7 (H3663), goat anti-rab-
bit immunoglobulin (IgG)-horseradish peroxidase (A6154), goat
anti-mouse IgG-horseradish peroxidase (A4416), and rabbit anti-goat
IgG-horseradish peroxidase (A4174) were obtained from Sigma-Aldrich.
Antibody for cleaved caspase 3 (p17) (rabbit polyclonal; 9661) was pur-
chased from Cell Signaling.
Plasmid constructs. The plasmid encoding the full-length TIA1a
(variant 2, NM_022173.2) has been described before (30). TIA1b (variant
1, NM_022037.2) and hnRNP K (variant 1, NM_002140.3) were ampli-
fied from total RNA of HeLa cells using the specific primers shown in
Table 1. The PCRproductswere digestedwithKpnI andEcoRI and cloned
into pcDHA as described previously (29). These plasmids were named
pcDHA-TIA1b and pcDHA-hnRNP K. These constructs express the in-
serted gene with the HA epitope at the N terminus of the protein. Expres-
sion of the proteins can be driven by either a CMV promoter or T7 pro-
moter located upstream of the coding sequences.
siRNA-mediated silencing. For depletion of PCBP1, PCBP2, TIA1,
and hnRNPK inHeLa, HEK293, Huh7,MCF-7, or BHK-21 cells, siRNAs
(pool of four different siRNAs) targeting PCBP1, PCBP2, TIA1 (catalog
numbers M-012243-01-0005, M-012002-01-0005, and L-013042-00-
0005, respectively; Dharmacon), and hnRNP K (catalog numbers
J-011692-05, -06, -07, and -08, respectively, for duplexes 1, 2, 3, and 4;
Dharmacon) were transfected at a final concentration of 10 to 20 nM
(except where indicated otherwise), according to the protocol of reverse
transfection, with Lipofectamine RNAiMax (Invitrogen) as recom-
mended by the manufacturer. At 24 h posttransfection (hpt), the trans-
fection mix was replaced with DMEM containing 10% FBS and PKS, and
the cells were incubated further for 40 to 48 h to allow knockdown of the
gene. A nontargeting (NT) siRNA (catalog number 1027281; Qiagen)
which does not target any of the known mammalian genes was used as a
control siRNA.
Plasmid DNA and RNP (or NC) transfection. Transfection of plas-
mids was performed using Lipofectamine 2000 (Invitrogen) as per the
manufacturer’s instructions. At 4 hpt, the transfection mix was replaced
with complete growth medium and incubated for 40 to 44 h before being
used for assays. Transfection of viral RNPs was also performed using the
same procedure as used for plasmid transfection and as described previ-
ously (29).
WB. Western blotting (WB) and quantification of the protein bands
were performed as described before (29). Concentrations of antibodies
used were as follows: M, 1:1,000 to 1:3,000; actin, 1:3,000 to 1:5,000; pro-
caspase 3 and PCBP2, 1:3,000; hnRNP K, 1:15,000; HA, 1:10,000; PCBP1,
TIA1, FLIP, Bad, Bak, andNoxa, 1:250 to 1:500 each; GS28, NF90, ADAL,
and cleaved caspase 3 (p17), 1:1,000 each. Secondary antibodies including
goat anti-rabbit immunoglobulin (IgG)-horseradish peroxidase, goat an-
ti-mouse IgG-horseradish peroxidase, and rabbit anti-goat IgG-horserad-
ish peroxidase were used at dilutions of 1:500 to 1:10,000.
qRT-PCR. The primers, probes, and the methods used for quantifica-
tion of VSVPmRNAand antigenomeRNAby quantitative real-time PCR
(qRT-PCR) were as described previously (33).
Semiquantitative RT-PCR. Total RNA from cells was extracted with
TRIzol (Invitrogen). First-strand cDNA was synthesized using total RNA
and oligo(dT) primer (Roche), followed by PCR amplification with spe-
cific primers (Table 1) to determine themRNA levels of anti- and proapo-
ptotic proteins. For an internal control, oligo(dT)-derived cDNA was
used to amplify ribosomal protein L32 (L32) mRNA using specific prim-
ers as described before (37). PCR cycling conditions used were 20 s at
94°C, 30 s at 54°C, and 30 s at 72°C for 28 to 40 cycles.
Cell viability assay andVSV entry assay based on luciferase activity.
A total of 2 104 HeLa cells/well were reverse transfected with 10 nMNT
or hnRNPK siRNA in opaque-walled, round-bottom, black 96-well plates
using Lipofectamine RNAiMax (Invitrogen). For cell viability assays, at 60
hpt, cells were washed with 1 phosphate-buffered saline (PBS) and then
mock infected or infected with VSV-eGFP at anMOI of 0.1 in a volume of
40l/well. After 1 h of incubation at 37°C, 60l of completemediumwas
added to each well, and the incubation continued for time points indi-
cated in the figures. Cell viabilitywas determined by directly adding 100l
of CellTiter-GloReagent (Promega) to eachwell as per themanufacturer’s
instructions. Luciferase activity was recorded in a Veritas Microplate Lu-
minometer (Turner Biosystems). For a VSV entry assay based on lucifer-
ase activity, at 60 hpt, the cells were infected with VSV-PLuc at anMOI of
Dinh et al.
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300 for 1 h on ice in a volume of 40 l/well, washed, and incubated at
37°C. At the time points indicated in the figures, luciferase assays were
performed by using a dual-luciferase assay kit (Promega).
Statistical analysis. Statistical analyses were performed using the
MIXED procedure of SAS (SAS Institute, Inc., Cary, NC). The statistical
model included “treatment” as a fixed effect. Data are presented as means
standard errors of means. A P value of 0.05 was considered statistically
significant.
RESULTS
hnRNP K is required for VSV infection. In a previous high-
throughput siRNA screening assay (33), we identified hnRNPK as
a cellular factor required forVSV infection. To understand further
the role of hnRNP K in VSV infection, we examined how deple-
tion of hnRNP K affects virus growth in cultured HeLa cells.
Treating the cells with a pool of siRNAs specific for hnRNP K
resulted in a greater than 90% reduction in the levels of hnRNP K
compared to those seen in cells treated with a nontargeting (NT)
siRNA or in mock-treated cells (Fig. 1A). Infection of hnRNP
K-depleted cells with VSV resulted in a 5- to 6-fold reduction in
viral protein expression, as examined by monitoring the levels of
the viral M protein, compared to those in NT siRNA-transfected
cells (Fig. 1A and B). Evaluation of viral growth kinetics revealed
that the virus growth was significantly attenuated in cells depleted
of hnRNP K at all time points examined. At a low multiplicity of
infection (MOI of 0.01), the virus yield at 24 h postinfection (hpi)
was reduced over 15-fold in hnRNP K-depleted cells compared to
the yield from control NT siRNA-treated cells (Fig. 1C). A similar
difference in growth kinetics and virus yield was also observed
with the use of a higher MOI (1.0), and the overall virus yield was
diminished by about 5-fold (data not shown). The requirement of
hnRNP K for VSV infection was also observed in MCF-7, Huh-7,
andHEK293 (data not shown) cells as well as inMEFs (see Fig. 4).
While depletion of hnRNP K resulted in significant inhibition of
VSV growth, ectopic expression of HA-tagged hnRNP K in cells
yielded reproducibly a 2-fold increase in viral protein expression,
as indicated by theM protein levels (Fig. 1D), and a similar 2-fold
increase in overall virus growth was observed (data not shown).
Taken together, the results from depletion and overexpression
studies suggest that hnRNP K is required for VSV growth and
infection.
The requirement for hnRNP K is primarily at the level of
virus propagation.To determine the step(s) at which hnRNPK is
required for VSV infection, we next examined the relative levels of
viral mRNA and full-length antigenomic RNAs synthesized in in-
fected cells depleted of hnRNP K. In VSV infection at a low MOI
(0.01), we observed that the levels of MmRNAs and antigenomic
RNAs in hnRNP K-depleted cells were significantly decreased,
representing approximately 20% of those in NT siRNA-treated
cells (Fig. 2A). This was consistently seen in infected cells at early
(6 h) (data not shown) and late times (12 h) (Fig. 2A) postinfec-
tion. However, at a high MOI (1.0), the reduction in viral mRNA
and antigenomic RNA levels in hnRNP K-depleted cells was less
pronounced. The levels of these RNAs were about 70% of those
seen in NT siRNA-treated cells (Fig. 2B). The observations that
viral RNA synthesis was less affected by hnRNP K depletion at a
high MOI (a condition in which most of the cells in the culture
were infected) but that it was significantly reduced at a lowMOI (a
condition in which majority of the cells in the culture were unin-
fected at early times of infection but could potentially be infected
with recently produced virions) suggest that although hnRNP K
TABLE 1 Primers used in this study
Primer name Primer sequence (5= to 3=)a Purpose
TIA1-KpnI-F ATATGGTACCATGGAGGACGAGATGCCCAAG Amplification and cloning of TIA1a and TIA1b
TIA1-EcoRI-R ATATGAATTCTCACTGGGTTTCATACCCTGCC
TIA1-KpnI-F ATATGGTACCATGGAGGACGAGATGCCCAAG Differentiation of TIA1a from TIA1b
TIA1-spliced-R GATCACCAACAAAGACATGGAAATG
hnRNPK-KpnI-F ATATGGTACCATGGAAACTGAACAGCCAG Amplification and cloning of hnRNP K
hnRNPK-EcoRI-R ATATGAATTCTTAGAAAAACTTTCCAGAATACTG
BclX-F CATATCAGAGCTTTGAACAG Differentiation of Bcl-XL from Bcl-XS
BclX-R TCATTTCCGACTGAAGAGTG
Bax-F CAGCTCTGAGCAGATCATG Amplification of Bax
Bax-R CACAGGGCCTTGAGCAC
Bik-F TCTCCAGAGACATCTTGATG Amplification of Bik
Bik-R GTTCGCAGGACACCCAG
Bid-F TGGACCGTAGCATCCCTC Amplification of Bid
Bid-R CAGTCCATCCCATTTCTGG
Mcl-1-F CGGGAGGGCGACTTTTG Amplification of Mcl-1
Mcl-1-R GAACTCCACAAACCCATCC
Bcl2-A1-F CAGTGCGTCCTACAGATAC Amplification of Bcl2-A1
Bcl2-A1-R GCCTTATCCATTCTCCTGTG
Bag1-F CAGCAATGAGAAGCACGAC Amplification of Bag1
Bag1-R TGCAGAGAGCTTCAGCTTG
Bcl-2-F CGATAACCGGGAGATAGTG Amplification of Bcl-2
Bcl-2-R CACCGTGGCAAAGCGTC
Bcl-W-F CTGGTGGCAGACTTTGTAG Amplification of Bcl-W
Bcl-W-R CATCCACTCCTGCACTTG
XIAP-F TGGCACGAGCAGGGTTTC Amplification of XIAP
XIAP-R CTCGGGTATATGGTGTCTG
a Underlined sequences indicate restriction sites.
Requirement of hnRNP K in VSV Infection
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may play a role in viral gene expression to some extent, it likely
plays a more prominent role(s) at another step (or other steps) in
the virus replication cycle.
To further elucidate the role of hnRNP K in the VSV life cycle,
we investigated the requirement of hnRNP K at VSV entry/un-
coating and assembly/budding steps. Transfection of VSVnucleo-
capsids (NCs) directly into cells bypasses the viral entry and un-
coating steps, resulting in expression of the viral genes (29, 33).
Thus, we examined the effect of depletion of hnRNP K on viral
gene expression in cells transfected with the viral NCs. Results
show that NC transfection led to only a slight decrease (approxi-
mately 30%) in the levels of the viralMprotein in cells treatedwith
siRNA for hnRNP K compared to levels in NT siRNA-transfected
cells (Fig. 2C, lanes 3 and 4). In contrast, an 8- to 10-fold reduction
in M protein levels was observed in cells infected at a low MOI
(0.01) with VSV (Fig. 2C, lanes 1 and 2). Infection of cells with
VSVG virus (a virus that lacks the G gene and cannot produce
infectious particles, thereby limiting the infection with this virus,
which is incompetent in budding, to a single cycle only) also led to
a slight decrease (approximately 30%) in the levels of the viral M
protein in hnRNP K siRNA-treated cells compared to the control
NT siRNA-treated cells (Fig. 2C, lanes 5 and 6). Furthermore,
using a highMOI (1.0) of VSV, we observed viral gene expression
at 4 hpi (a time at which viral gene expression is readily detectable
FIG 1 hnRNP K is required for VSV infection. (A) Suppression of VSV rep-
lication in cells depleted of hnRNP K. HeLa cells were transfected with 10 nM
siRNA for NT (lane 2) or 10 nM and 20 nM hnRNP K (siK) (lanes 3 and 4,
respectively) for 60 h. Cells were then infected with VSV at anMOI of 0.01 for
12 h. Equal amounts of cell lysates were analyzed by WB with anti-hnRNP K
and anti-M antibodies. Actin served as the loading control. (B) Quantification
of M protein levels (arbitrary units) from three independent experiments as
described in panel Awith error bars representing the standard errors ofmeans.
The level of M expression in the NT siRNA-treated sample was set at 1. ***,
P 0.001. (C)Multicycle growth of VSV in cells depleted of hnRNPK. siRNA
(10 nM) treatment and virus infections were performed as described in panel
A; virus titers in supernatants collected at indicated time points were deter-
mined by plaque assay and are expressed as log10 PFU/ml. Statistical signifi-
cance was determined for virus titers at 12, 18, and 24 hpi. ***, P 0.001. (D)
VSV infection is enhanced in hnRNP K-overexpressing cells. HeLa cells trans-
fectedwith 1.5g of empty vector (EV) or anHA-hnRNPK (HA-K)-encoding
plasmid for 48 h were infected with VSV at an MOI of 0.01 for 12 h, and cell
lysates were analyzed byWB using anti-M or anti-HA antibodies. Actin served
as the loading control. , anti; siK, siRNA targeting hnRNP K.
FIG 2 hnRNP K is required for VSV propagation. (A and B) VSVmRNA and
antigenomic RNA levels in cells depleted of hnRNP K and infected with the
virus at a low (0.01) or high (1.0) MOI (panels A and B, respectively) were
determined by qRT-PCR. Experimental conditions were as described in the
legend of Fig. 1A. Error bars represent the standard errors ofmeans from three
independent experiments. ***, P  0.001; *, P  0.05. (C) hnRNP K is not
required for early stages of the VSV life cycle. HeLa cells were transfected with
10 nM siRNA for NT or targeting hnRNPK for 60 h. Cells were then treated as
follows: infected with VSV at an MOI of 0.01 for 12 h (lanes 1 and 2), super-
transfected for 6 h with viral NC prepared from VSV (lanes 3 and 4), infected
with VSVG at an MOI of 0.5 for 8 h (lanes 5 and 6), or infected with VSV at
anMOI of 1 for 4 h (lane 7 and 8). Cell lysates corresponding to equal amounts
of total proteins were analyzed by WB with anti-hnRNP K and anti-M anti-
bodies. Actin served as the loading control. (D) HeLa cells were transfected
with siRNA as described in the legend of Fig. 1A. At 60 hpt, cells were infected
with VSV-PLuc at an MOI of 300. After 1 h of virus adsorption on ice, cells
were washed with PBS, and cell extracts at various times postincubation were
analyzed for luciferase activity. The luciferase activity in NT siRNA-treated
cells at various times postinfection was set at 1. Data show relative luciferase
activity and are expressed as the averages of three independent experiments,
with error bars representing the standard errors of means. NS, nonsignificant.
(E) HeLa cells were transfected with siRNA as described in the legend of Fig.
1A. At 60 hpt, cells were infected with VSV-PeGFP at an MOI of 0.05 or
VSVG at an MOI of 0.5 for 12 h. The percentages of infected cells were
determined by counting the number of cells expressing green fluorescence
from PeGFP. Data show relative percent infection after normalizing the value
of cells treated with siRNA targeting hnRNP K to that of NT siRNA-treated
cells, which is set at 100, and are expressed as average of three independent
experiments with error bars representing the standards error of means. ***,
P 0.001; NS, nonsignificant.
Dinh et al.
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but virus assembly/budding is minimal) to be reduced by only
about 30% in cells treated with an siRNA for hnRNP K (Fig. 2C,
lanes 7 and 8) compared to that in NT siRNA-transfected cells.
These results show that bypassing entry/uncoating steps (NC
transfection), using assembly/budding-incompetent (VSVG)
virus, or using high MOIs did not adversely affect overall viral
gene expression. On the other hand, a significant reduction in
viral gene expression under conditions of VSV infection at a low
MOI suggests that the supportive roles of hnRNP K in VSV infec-
tion are manifested when the infection undergoes multiple cycles,
indicating that this cellular proteinmay be involved in virus entry/
uncoating or assembly/budding steps.
To determine if virus entry and uncoating steps are affected by
depletion of hnRNP K, we used a recombinant virus (VSV-PLuc)
which encodes a P-luciferase (P-Luc) fusion protein, in which the
entire coding region of luciferase is fused in frame following
amino acid 196 of the P protein. The VSV-PLuc virus is similar to
VSV-PeGFP described previously (35) and incorporates P-Luc
within virus particles. Luciferase activity can be readily detected in
extracellular virions and in infected cells (data not shown). Cells
transfected with NT or hnRNP K siRNA were infected with VSV-
PLuc at an MOI of 300 to allow readily detectable levels of lucif-
erase. Following virus adsorption on ice, cells were washed, and
luciferase activity was determined in extracts of cells at 0, 0.5, 1,
and 1.5 h postincubation at 37°C to enable virus entry and uncoat-
ing. Results (Fig. 2D) show that luciferase activity in these cells was
not significantly affected in the presence or absence of hnRNP K,
indicating that this protein does not play any discernible role in
virus entry and uncoating steps. Furthermore, using a low MOI
(0.01), a multicycle virus growth condition, we observed that the
percentage of cells infected with wt VSV increased with time in
the presence of hnRNP K, while in cells depleted of hnRNP K, the
relative percentage of infected cells remained low, reaching up to
about 15% of that of NT siRNA-treated cells at 16 hpi (Fig. 2E).
On the other hand, we found no differences in the percent infec-
tionwhen these cells were infected with the budding-incompetent
VSVG (Fig. 2E). Taken together, the results suggest that hnRNP
K is required for virus egress in infected cells and that its depletion
may negatively affect assembly and/or release of virus required for
further rounds of infection.
hnRNP K alters the expression of TIA1, a known negative
regulator of VSV replication. Since hnRNP K is known to influ-
ence expression of many cellular genes, we wondered whether its
depletion alters expression of cellular genes that have been shown
to be involved in VSV replication. Previous studies from our lab-
oratory showed that PCBP2 and PCBP1 as well as TIA1 inhibit
VSV replication (29, 30). Thus, we examined the levels of these
proteins in cells depleted of hnRNP K by siRNA transfection. Fig-
ure 3A shows that knockdown of hnRNP K had no measurable
effect on the levels of PCBP1/2. Expression levels of another cel-
lular protein, NF90, which is known to inhibit replication of sev-
eral other viruses such as HIV-1 (38), Ebola virus (39), and influ-
enza virus (40), was also not affected by hnRNP K depletion (Fig.
3A). Interestingly, under this condition, we observed a reproduc-
ibly greater than 2-fold increase in the total amount of TIA1 pro-
tein (Fig. 3B and C). Strikingly, hnRNP K depletion resulted in a
FIG 3 hnRNP K regulates the expression of the two isoforms of TIA1 but not PCBP1/2. (A) Depletion of hnRNP K does not affect the expression of PCBP1/2.
HeLa cells were transfected with NT or hnRNP K siRNA at a concentration of 10 nM, and at 60 hpt, cells were infected with VSV at anMOI of 0.01 for 12 h. Cell
lysates were used forWB to detect the indicated proteins. (B to D) hnRNP K depletion results in increased levels of total TIA1 and the TIA1b isoform. HeLa cells
were mock transfected or transfected with NT or hnRNP K siRNA as a pool of four duplexes (pooled) or as individual duplexes (si DX1 to si DX4) at a
concentration of 10 nM, and at 60 hpt, the cells were infected with VSV at anMOI of 0.01 for 12 h. Cell lysates were used forWB to detect the indicated proteins
(B). Quantification of total TIA1 protein levels (arbitrary units) from three independent experiments is shown in panel C while the levels of TIA1a and TIA1b
isoforms are shown in panel D. The level of TIA1a expression in the NT siRNA-treated sample was set at 1. ***, P 0.001; **, P 0.01. (E) Switching of TIA1
isoform expression is regulated by hnRNP K protein at the mRNA level. The experiment was done as described in panel B. Total RNA was subjected to
semiquantitative RT-PCR to detect the two isoforms of TIA1. Ribosomal protein (RP) L32mRNA served as an internal control. (F)Overexpression of TIA1a and
TIA1b inhibits VSV gene expression. HeLa cells transfected with 1.5 g of empty vector (EV) or HA-TIA1a- or HA-TIA1b-encoding plasmids for 48 h were
infected with VSV at anMOI of 0.1 for 12 h (lanes 1 to 3) or with VSVG at anMOI of 0.5 for 8 h (lanes 4 to 6) or supertransfected for 6 h with viral NC prepared
fromVSV (lanes 7 to 9), and cell lysates were analyzed byWB using anti-M or anti-HA antibodies. Actin served as the loading control. siPCBP1, siRNA targeting
PCBP1; siPCBP2, siRNA targeting PCBP2; siTIA1, siRNA targeting TIA1.
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dramatic shift in the ratio of the two isoforms (TIA1a and TIA1b)
of the protein (Fig. 3B and D). In mock-treated or NT siRNA-
treated cells, the amount of TIA1b was approximately 12% of
TIA1a, whereas in hnRNPK-depleted cells, TIA1b was detected at
significantly higher levels (about 3-fold) than TIA1a (Fig. 3B).
These results were observed when individual siRNAs specific for
hnRNP K or pooled siRNAs were used (Fig. 3B), indicating that
the effect of hnRNP K protein on altered expression of TIA1 iso-
forms was not due to off-target effects. The altered expression of
the two isoforms was detected at the mRNA level (Fig. 3E), indi-
cating that hnRNP K regulates the expression of these two iso-
forms at the transcription and/or splicing level. Similar results
were also obtained inHEK293 cells (data not shown) andwtMEFs
(see Fig. 4D).
Since depletion of hnRNP K led to increased levels of the
TIA1b isoform and inhibition of virus replication, we examined
whether TIA1b inhibits VSV replication, as was demonstrated for
the TIA1a isoform previously (30). In VSV-infected cells overex-
pressing HA-tagged TIA1b, the viral M protein levels were re-
duced (Fig. 3F). The reduction inMprotein levels was observed in
TIA1b-expressing cells infected with VSV (Fig. 3F, lanes 1 to 3) or
VSVG (lanes 4 to 6) or in NC-transfected cells (lanes 7 to 9),
suggesting that TIA1b inhibits VSV replication. Thus, it appears
that hnRNP K depletion results in increased accumulation of
TIA1b, which is also responsible for inhibition of VSV replication.
hnRNP K is required for survival of VSV-infected cells. hn-
RNPKplays essential roles in cell survival. Its cleavage by different
granzymes initiates cell death processes, and its depletion primes
the cells to undergo programmed cell death under various apo-
ptotic stimuli (9, 13, 41, 42). While performing our studies, we
observed that VSV-infected cells depleted of hnRNP K exhibited
enhanced cytopathic effects and cell death compared to the in-
fected cells not depleted of the protein. Therefore, we examined if
hnRNP K plays any role in cell survival during VSV infection.
Depletion of hnRNP K did not affect the viability of mock-in-
fected cells significantly; however, the viability of VSV-infected
cells was significantly reduced with time postinfection (Fig. 4A).
The results show that viability of VSV-infected cells depleted of
hnRNP K was reduced to approximately 63% and 25% at 12 and
18 hpi, respectively, whereas the viability of NT siRNA-treated
cells infected with VSVwas reduced only to 92% and 60%, respec-
tively, at the corresponding times postinfection (Fig. 4A). Consis-
tent with the increase in cell death, the amount of cleaved caspase
3 (p17) was found to be 7-fold higher in cells lacking hnRNP K at
12 hpi (Fig. 4B and C).
Since TIA1 is a proapoptotic protein (43, 44), we wondered if
the upregulation of TIA1 in hnRNP-depleted cells is responsible
for the enhanced apoptosis observed in these cells infected with
VSV. To this end, we examined the apoptosis occurring in wt and
TIA1/ MEFs (34) when hnRNP K is silenced by siRNA and
FIG 4 hnRNP K is required for survival of VSV-infected cells. (A) Knockdown of hnRNP K reduces cell survival during VSV infection. HeLa cells were
transfected with NT or hnRNP K siRNA at concentration of 10 nM for 60 h. Cells were mock infected or infected with VSV at an MOI of 0.01. At 6, 12, and 18
hpi, cell survival was determined by a CellTiter-Glo Kit. The percentage of cell viability in NT siRNA-transfected and mock-infected culture at the beginning of
infection was set at 100%. Data from three independent experiments are shown with error bars representing the standard errors of means. **, P  0.01; NS,
nonsignificant. (B) Caspase 3 activation is more pronounced in infected cells lacking hnRNPK. The experiment was conducted as described in panel A. Infected
cells were lysed and analyzed at the indicated time points to detect procaspase 3, activated caspase 3 (p17), hnRNPK, andVSVMprotein using specific antibodies.
Actin served as a loading control. (C)Quantification of p17 protein levels (arbitrary units) from three independent experiments as described in panel B. The level
of activated caspase 3 (p17) in cells treated with siRNA targeting hnRNP K at 18 hpi was set arbitrarily at 1, and the relative levels of p17 in other samples were
thendetermined. Error bars represent the standard errors ofmeans from three independent experiments. ***, 0.001; **,P 0.01. (D)wtMEForTIA1/MEF
cells were transfected with NT or hnRNP K siRNA at a concentration of 20 nM for 60 h. Cells were mock infected (mock) or infected with VSV at an MOI of 1.
At 4 and 8 hpi, cells were lysed and subjected to WB with the indicated antibodies. (E) Quantification of p17 levels (arbitrary units) from three independent
experiments, with error bars representing the standard errors of means. The level of p17 in wtMEFs treated with siRNA targeting hnRNP Kwas set arbitrarily at
1, and the relative levels of p17 in other samples were then determined. ***, P 0.001.
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subsequently infectedwithVSV. Results (Fig. 4D and E) show that
activation of caspase 3 (as measured by the levels of p17) occurred
to similar extents in VSV-infected wt and TIA1/MEFs depleted
of hnRNP K, indicating that VSV-induced cell death in hnRNP
K-depleted cells is independent of TIA1.
VSV-mediated cell death in hnRNP K-depleted cells is asso-
ciated with increased levels of proapoptotic proteins and de-
creased levels of antiapoptotic proteins. VSV infection upregu-
lates the expression of proapoptotic proteins such as Noxa and
Bak that are involved in virus-mediated apoptosis in cell culture
(45–47). On the other hand, hnRNP K is known to support the
expression of antiapoptotic proteins such as the caspase inhibitor
protein XIAP (X-linked inhibitor of apoptosis protein) (12),
FLICE-inhibitory protein (FLIP) (9), and Bcl-XL but suppresses
the expression of proapoptotic Bcl-XS (42). Therefore, we exam-
ined if depletion of hnRNPK affects the expression of anti- and/or
proapoptotic proteins that may result in altered survival of VSV-
infected cells. Our results show that the levels of Noxa, Bad, and
FLIP were unchanged while the expression of Bak decreased in
both HeLa and HEK293 cells depleted of hnRNP K and infected
withVSV (Fig. 5A). Through semiquantitative RT-PCR,we found
that themRNA levels of proapoptotic factors Bax andBidwere not
altered significantly in the absence of hnRNP K, whereas the level
of another proapoptotic factor, Bik, was upregulated over 4-fold
(Fig. 5B). The mRNA levels of antiapoptotic factors Bag1 and
Bcl-2A1 but not Bcl-W or XIAP under similar experimental con-
ditionswere slightly reduced, whereas the level of Bcl-2was down-
regulated greater than 3-fold (Fig. 5C).
A previous study reported that depletion of hnRNP K by
siRNA treatment led to a significant decrease in the level ofmRNA
for the antiapoptotic protein Bcl-XL and an increase in the pro-
apoptotic Bcl-XS mRNAs in PC-3 cells as well as several other cell
lines, but no significant differences were observed in HeLa cells
(42), which was suggested to be due to less efficient depletion of
the protein in this cell line. Therefore, it was of interest to examine
the mRNA levels of Bcl-XL and Bcl-XS in HeLa cells depleted of
greater than 90% of hnRNP K using the pool of four siRNAs
described in our studies above (Fig. 1A). Results from such an
experiment show (Fig. 5B) that the mRNA levels of Bcl-XL and
Bcl-XS remained unchanged in VSV-infected HeLa cells depleted
of hnRNPKcompared to levels in the infected cells not depleted of
the protein. In contrast to the results in HeLa cells, we observed a
significant decrease of Bcl-XL and a concomitant increase in
Bcl-XS mRNA levels in HEK293 cells under similar experimental
conditions (Fig. 5D). Interestingly, the level of BikmRNAwas also
reduced significantly (Fig. 5D). These results indicate that the
VSV-mediated apoptosis in hnRNP K-depleted cells is associated
with alterations in the balance of pro-/antiapoptotic Bcl-2 pro-
teins (decrease of antiapoptotic proteins such as Bcl-XL, Bag1, and
Bcl-2 and an increase of proapoptotic factors includingBcl-XS and
Bik) though the identity of these proteins might differ in different
cell lines.
hnRNPKmaintains expression of cellular proteins required
for VSV infection. Since hnRNP K is involved in regulating ex-
pression of many cellular genes (1), it is possible that depletion of
hnRNP K might influence levels of cellular proteins that are
known to be required for VSV replication, leading to inhibition of
virus replication. Recently, we reported through a genome-wide
siRNA screen the requirement of several host factors for VSV rep-
lication at various stages of the virus infection cycle (33). Among
these, alanine deaminase-like (ADAL) protein was shown to be
required for the VSV assembly/budding step, whereas GBF1,
ARF1, and the proteins of the coatomer I (COPI) complex were
required for VSV genome transcription and replication (33, 48).
Therefore, we examined if hnRNP K silencing affects the expres-
sion of some of these cellular factors. Results show that hnRNP K
FIG 5 VSV-mediated cell death in hnRNPK-depleted cells is associated with increased levels of proapoptotic proteins Bcl-XS and Bik. (A)HeLa orHEK293 cells
transfectedwith siRNAs for 60 hwere infectedwith VSV at anMOI of 1 for 6 h. The levels of proapoptotic proteins Bak, Bad, Noxa, and antiapoptotic factor FLIP
were detected by WB using specific antibodies. (B and C) mRNA levels of proapoptotic proteins (B) or antiapoptotic proteins (C) in hnRNP K-depleted HeLa
cells infected with VSV. siRNA treatment and virus infections were performed as described in panel A. Total RNA was converted to cDNA using oligo(dT)
primers followed by PCR with specific primers. The mRNA level of cellular ribosomal protein L32 was used as an internal control. A DNA ladder (bp) is shown
on the right. Values at the top or bottom of the lanes represent relative levels of mRNAs, using levels in the NT lane as 1. The Bcl-XS level is relative to the Bcl-XL
level in the NT lane. The asterisk indicates the DNA product of an undocumented isoform of Bag1 or a nonspecific product. (D) mRNA levels of antiapoptotic
or proapoptotic proteins in hnRNPK-depletedHEK293 cells infectedwithVSV. siRNA treatment, virus infection, andmRNAdetectionwere as described above.
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depletion by siRNA did not alter the levels of COPI proteins such
as COPB1 and COPZ or GBF1 (Fig. 6A). Furthermore, under the
same conditions, the level of GS28, a putative protein of the cis-
Golgi compartment that is involved in endoplasmic reticulum
(ER)-Golgi transport (49) and apoptosis (50, 51), was not affected
either (Fig. 6A). On the other hand, depletion of hnRNP K re-
sulted in a 3- to 4-fold reduction in the levels of ARF1 and ADAL
proteins (Fig. 6B and C). These results suggest that hnRNP K
regulates expression of certain cellular proteins required for VSV
replication.
DISCUSSION
hnRNPK is amultifunctional protein in the subfamily of hnRNPs
which carry three KH domains and is involved in gene expression
and mRNA metabolism. Previously, our genome-wide screening
study identified hnRNP K as a factor required for VSV infection
(33). In this communication, we conducted further studies to de-
cipher the role of hnRNP K in supporting VSV infection. Our
results reveal that hnRNP K primarily supports VSV infection at
the level of virus propagation, but it is also involved in viral repli-
cation and transcription to some extent (Fig. 1 and 2). Further
studies showed that hnRNP K is required for suppressing apopto-
sis induction and promoting survival of infected cells, which in
turn supports VSV growth. We found that hnRNP K helps main-
tain the low levels of expression of proapoptotic proteins such as
BiK and Bcl-XS and the high levels of expression of antiapoptotic
proteins such as Bcl-XL, Bag1, and Bcl-2. In addition to the role of
hnRNP K in cell death suppression, our study found that hnRNP
K supports expression of several cellular factors required for VSV
replication and downregulates expression of some of the cellular
factors known to inhibit VSV replication. Thus, the studies pre-
sented here reveal critical roles of hnRNP K in VSV infection
through multiple mechanisms. The supportive role of hnRNP K
inVSV infection is observed in all cell lines examined in this study,
whereas its role in suppression of apoptosis is mediated by a bal-
ance between several pro- and antiapoptotic factors and is cell type
dependent.
hnRNP K is reported to play diverse roles in many virus infec-
tions. Its interactions with viral components and/or cellular fac-
tors support the replication of viruses, including enterovirus 71,
Sindbis virus, dengue virus, chikungunya virus, hepatitis C virus,
HBV, HIV-1, HSV-1, African swine fever virus, human cytomeg-
alovirus, and Epstein-Barr virus (16, 18–28). Interestingly, in hu-
man cytomegalovirus-infected cells, hnRNP K is essential for vi-
rus replication as it promotes the viability of infected cells (28).
Although our studies reveal such a role for hnRNP K in VSV
replication, it may also be involved in virus assembly and/or re-
lease. So, how then does hnRNP K facilitate VSV assembly and/or
release from infected cells? The answer to this critical question
requires further investigation, including examination of interac-
tions of viral proteins with hnRNP K. It is possible that hnRNP K
may directly or indirectly interact with the viral components to
mediate virus assembly or egress. Since hnRNP K is known to be
involved in cellular gene expression and signal transduction (3), it
is also possible that it modulates expression of certain cellular
proteins that are important for VSV egress, such as ADAL (Fig. 6B
and C), which was shown before to be required for VSV assembly
and budding (33). Alternatively, hnRNP K may recruit factors
necessary for virus egress through its K protein-interacting (KI)
domain.
Although interaction of VSV proteins with hnRNP K is being
examined currently, one required role for hnRNPK in VSV infec-
tion is found to be at the level of maintaining the viability of
infected cells. VSV-infected cells exhibited significantly reduced
cytopathic effects and did not undergo apoptosis as fast in the
presence of hnRNPK as in cells lacking this protein. Thus, hnRNP
K suppresses VSV-induced apoptosis. Examination of the levels of
FIG6 hnRNPK regulates expression of cellular proteins required forVSV infection. (A andB)HeLa cells transfectedwith siRNA for 60 hwere infectedwithVSV
at an MOI of 0.01 for 12 h. The levels of the proteins were detected by WB using specific antibodies. (C) Quantification of ADAL and ARF1 protein levels
(arbitrary units) from three independent experiments, with error bars showing the standard errors of means. The level of ADAL or ARF1 in the NT lane was
arbitrarily set at 1. **, P 0.01. (D) Involvement of hnRNP K in regulating expression of cellular proteins that affect VSV infection. hnRNP K inhibits TIA1a/b
expression, which is known to inhibit VSV replication. Increased levels of antiapoptotic proteins such as Bcl-XL, Bag1, and Bcl-2 and/or reduction in the levels
of apoptotic proteins Bcl-XS and Bik promotes cell survival for increased VSV replication, while maintenance of factors such as ADAL and ARF1 is required for
VSV replication.
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several factors involved in apoptosis suggested that increased
apoptosis of VSV-infected cells lacking hnRNPK does not involve
Noxa and Bak, two proapoptotic proteins previously shown to
mediate VSV-induced cell death (45–47). Rather, significantly in-
creased levels of Bik or Bcl-XS appear to regulate apoptosis in
hnRNP K-depleted cells by regulating the balance of the pro-/
antiapoptotic Bcl-2 proteins. In HeLa cells, the levels of Bcl-XS
remained unchanged in the presence or absence of hnRNP K, but
Bik was upregulated over 4-fold, which presumably was responsi-
ble for increased cell death. In contrast, in HEK293 cells, Bcl-XS
levels were increased significantly in the absence of hnRNP K
along with decreased levels of Bcl-XL while the level of Bik was
significantly reduced, suggesting that in this cell type, the decrease
in the Bcl-XL/Bcl-XS ratio may primarily regulate apoptosis of
VSV-infected cells. Thus, it appears that hnRNP K regulates the
balance between pro- and antiapoptotic factors in a cell-type-de-
pendent manner so as to allow infected cells to survive longer for
increased virus growth. It should be noted, however, that consid-
ering the multiple roles played by hnRNP K in many cellular pro-
cesses, it is possible that suppression of apoptosismay not be solely
responsible for increased growth of VSV in infected cells. Further
studieswould have to be conducted to delineate additional roles of
hnRNP K, if any, in supporting VSV growth.
hnRNP K is known to function closely with p53, a well-known
mediator of apoptosis, at multiple levels to coregulate cell fate.
Together with p53, hnRNP K binds to promoters to upregulate a
number of genes encoding DNA damage response factors (52),
and in combination with large intergenic noncoding RNA p21
(lincRNA-p21), it regulates global gene repression downstream of
a p53-mediated response (53). Evidence also suggests that hnRNP
K acts as a cell survival enhancer independent of p53 bymaintain-
ing a high level of antiapoptotic proteins, including FLIP and
XIAP (9, 12). Studies presented here reveal that the role of hnRNP
K in survival of VSV-infected cells is independent of its interaction
with p53. This interpretation is consistent with the observations
that VSV-induced apoptosis in the absence of hnRNP K occurs
with similar kinetics in both p53-inactive cells (HeLa and
HEK293) and wild-type p53-active cells such as MCF-7 and MEF
cells. Additionally, apoptosis induced by other factors such as cy-
cloheximide treatment or other virus infections (lymphocytic
choriomeningitis virus [LCMV] and human parainfluenza virus
type 3 [HPIV3]) was also enhanced in hnRNP K-depleted cells
(data not shown). These observations highlight the essential role
of hnRNPK independent of p53 in protecting cells from apoptosis
triggered by different stimuli.
VSV is being used as an oncolytic agent for various types of
tumors (55–58). One of the hallmark features of most cancer cells
is the defective type I interferon response and signaling (59),
which allows viruses such as VSV to grow rapidly and kill the cells.
hnRNP K is upregulated in many types of cancerous cells (10, 11,
60) and is considered a prognostic marker and a target for tumor
therapy (11, 61). The results showing that hnRNPK supports VSV
propagation further add to the understanding of why tumors pro-
vide an appropriate microenvironment for VSV growth.
Our studies also reveal a novel role of hnRNP K in suppressing
not only the expression of the TIA1b isoform (a differentially
spliced isoform of TIA1a) but also the overall levels of TIA1. The
function of these two isoforms in cells is poorly understood, ex-
cept that TIA1b displays greater splicing-stimulatory activity than
TIA1a (62). Previously, we along with others demonstrated that
TIA1 inhibited VSV replication (30, 63) although the contribu-
tion of the TIA1b isoform was not investigated. Our present re-
sults demonstrate that TIA1b is inhibitory to VSV replication.
Since expression of TIA1 is mediated by many cellular factors
includingmiRNAs (64, 65), it would be of interest to examine how
hnRNP K regulates or is regulated by these factors, which may
provide further understanding of the role of cellular factors in-
volved in VSV replication.
The results presented here do not exclude the involvement of
hnRNP K in supporting VSV assembly and budding. Although
not much is known about the direct role(s) of hnRNP K in lipid
metabolism, in protein trafficking, in the growth of plasmamem-
brane, or in secretory pathways, which are directly involved in
virus assembly and budding, hnRNPK regulates the expression of
15-lipoxygenase, a key enzyme in the metabolism of phospholip-
ids and internal membrane (66). Studies of the hnRNP K interac-
tome revealedmore than 100 interacting partners and determined
that hnRNP K protein is present in the nucleus, cytoplasm, mito-
chondria, and the vicinity of the plasma membrane (31). Thus, it
is possible that hnRNPK exerts its positive impact on VSV growth
through one or more of its interacting partners.
In summary,we demonstrate here a role(s) of hnRNPK inVSV
infection (Fig. 6D). The mechanisms by which hnRNP K pro-
motes VSV infection involve the following: (i) promoting cell sur-
vival via suppression of proapoptotic proteins (Bik and Bcl-XS)
and upregulation of antiapoptotic proteins (Bcl-XL, Bag1, and
Bcl-2); (ii) suppression of expression of VSV-inhibitory protein
TIA1; and (iii) upregulation of cellular factors favoring VSV in-
fection such as ARF1 and ADAL. Our data also provide a better
understanding of why tumor cells provide a more conducive en-
vironment for VSV replication. Overall, our studies presented
here suggest a multifunctional role of hnRNP K in VSV infection
and prompt us to undertake additional research to uncover its
involvement in virus-host interactions.
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